Published in N Engl J Med on October 27, 2005
Screening for breast cancer: an update for the U.S. Preventive Services Task Force. Ann Intern Med (2009) 11.96
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst (2009) 10.91
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA (2006) 6.45
Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society. JAMA (2015) 6.38
Rate of over-diagnosis of breast cancer 15 years after end of Malmö mammographic screening trial: follow-up study. BMJ (2006) 5.82
Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med (2009) 5.68
Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med (2009) 4.60
Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol (2008) 4.42
Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness. Ann Intern Med (2011) 4.28
Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol (2009) 3.74
Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts. Ann Intern Med (2014) 3.46
The benefits and harms of breast cancer screening: an independent review. Br J Cancer (2013) 3.43
Improvements in US Breast Cancer Survival and Proportion Explained by Tumor Size and Estrogen-Receptor Status. J Clin Oncol (2015) 3.19
Breast cancer mortality in organised mammography screening in Denmark: comparative study. BMJ (2010) 2.99
Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer (2016) 2.91
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol (2012) 2.85
Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. J Clin Oncol (2014) 2.82
Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol (2009) 2.74
Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). J Clin Oncol (2014) 2.74
Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control (2007) 2.69
Trends and Patterns of Disparities in Cancer Mortality Among US Counties, 1980-2014. JAMA (2017) 2.63
Targeting breast cancer stem cells. J Clin Oncol (2010) 2.53
Effect of very small tumor size on cancer-specific mortality in node-positive breast cancer. J Clin Oncol (2011) 2.52
Applying what we know to accelerate cancer prevention. Sci Transl Med (2012) 2.43
Comparing care for breast cancer survivors to non-cancer controls: a five-year longitudinal study. J Gen Intern Med (2009) 2.36
Underlying causes of the black-white racial disparity in breast cancer mortality: a population-based analysis. J Natl Cancer Inst (2009) 2.33
Is breast cancer the same disease in Asian and Western countries? World J Surg (2010) 2.33
Racial and ethnic differences in breast cancer survival: how much is explained by screening, tumor severity, biology, treatment, comorbidities, and demographics? Cancer (2008) 2.23
Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol (2009) 2.20
Task-based assessment of breast tomosynthesis: effect of acquisition parameters and quantum noise. Med Phys (2010) 2.06
Tipping the balance of benefits and harms to favor screening mammography starting at age 40 years: a comparative modeling study of risk. Ann Intern Med (2012) 1.99
Cost-effectiveness of digital mammography breast cancer screening. Ann Intern Med (2008) 1.95
Race-specific impact of natural history, mammography screening, and adjuvant treatment on breast cancer mortality rates in the United States. Cancer Epidemiol Biomarkers Prev (2010) 1.93
Modern mammography screening and breast cancer mortality: population study. BMJ (2014) 1.92
Declining death rates reflect progress against cancer. PLoS One (2010) 1.91
Timeliness of breast cancer diagnosis and initiation of treatment in the National Breast and Cervical Cancer Early Detection Program, 1996-2005. Am J Public Health (2009) 1.90
Update on pancreatic intraepithelial neoplasia. Int J Clin Exp Pathol (2008) 1.87
Proliferative genes dominate malignancy-risk gene signature in histologically-normal breast tissue. Breast Cancer Res Treat (2009) 1.83
Cancer screening among patients with advanced cancer. JAMA (2010) 1.82
An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. Cancer Cell (2011) 1.78
Breast cancer survivors' perceptions of survivorship care options. J Clin Oncol (2011) 1.72
Second solid cancers after radiotherapy for breast cancer in SEER cancer registries. Br J Cancer (2009) 1.69
Epithelial-mesenchymal transition, cancer stem cells and treatment resistance. Breast Cancer Res (2012) 1.68
The molecular pathology of breast cancer progression. J Pathol (2010) 1.65
Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer. Breast Dis (2010) 1.64
Socioeconomic status and survival after an invasive breast cancer diagnosis. Cancer (2010) 1.62
How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists. PLoS One (2012) 1.61
Higher population-based incidence rates of triple-negative breast cancer among young African-American women : Implications for breast cancer screening recommendations. Cancer (2011) 1.59
Benefits and harms of mammography screening after age 74 years: model estimates of overdiagnosis. J Natl Cancer Inst (2015) 1.56
Mammography screening of women in their 40s: impact of changes in screening guidelines. Cancer (2008) 1.54
Advanced breast cancer incidence following population-based mammographic screening. Ann Oncol (2011) 1.53
Self-detection remains a key method of breast cancer detection for U.S. women. J Womens Health (Larchmt) (2011) 1.53
Cancer statistics for Asian Americans, Native Hawaiians, and Pacific Islanders, 2016: Converging incidence in males and females. CA Cancer J Clin (2016) 1.53
Variation in tumor natural history contributes to racial disparities in breast cancer stage at diagnosis. Breast Cancer Res Treat (2013) 1.53
Calibration methods used in cancer simulation models and suggested reporting guidelines. Pharmacoeconomics (2009) 1.48
Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes. J Clin Oncol (2008) 1.46
Breast cancer tumor growth estimated through mammography screening data. Breast Cancer Res (2008) 1.43
The Effect of Treatment Advances on the Mortality Results of Breast Cancer Screening Trials: A Microsimulation Model. Ann Intern Med (2016) 1.41
Biomarkers in Breast Cancer - An Update. Geburtshilfe Frauenheilkd (2012) 1.41
Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination. Popul Health Metr (2007) 1.39
New markers of pancreatic cancer identified through differential gene expression analyses: claudin 18 and annexin A8. Am J Surg Pathol (2008) 1.39
The first national public breast cancer screening program in Saudi Arabia. Ann Saudi Med (2010) 1.39
EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Ann Oncol (2012) 1.37
Online tool to guide decisions for BRCA1/2 mutation carriers. J Clin Oncol (2012) 1.35
Secular trends in mortality from common cancers in the United States by educational attainment, 1993-2001. J Natl Cancer Inst (2008) 1.34
Breast cancer screening, area deprivation, and later-stage breast cancer in Appalachia: does geography matter? Health Serv Res (2013) 1.32
Simulation models of obesity: a review of the literature and implications for research and policy. Obes Rev (2010) 1.31
Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G. Mol Cancer Ther (2009) 1.31
Benefits, harms, and costs for breast cancer screening after US implementation of digital mammography. J Natl Cancer Inst (2014) 1.27
Health Behaviors, Mental Health, and Health Care Utilization Among Single Mothers After Welfare Reforms in the 1990s. Am J Epidemiol (2016) 1.27
Role of microRNAs in the regulation of breast cancer stem cells. J Mammary Gland Biol Neoplasia (2012) 1.25
Breast cancer mortality in participants of the Norwegian Breast Cancer Screening Program. Cancer (2013) 1.25
Validation of population-based disease simulation models: a review of concepts and methods. BMC Public Health (2010) 1.23
What does the population attributable fraction mean? Prev Chronic Dis (2006) 1.23
Increasingly strong reduction in breast cancer mortality due to screening. Br J Cancer (2011) 1.22
Education, survival and avoidable deaths in cancer patients in Finland. Br J Cancer (2010) 1.21
Immunoimaging of CXCR4 expression in brain tumor xenografts using SPECT/CT. J Nucl Med (2009) 1.19
Balancing harms and benefits of service mammography screening programs: a cohort study. Breast Cancer Res (2012) 1.19
Molecular mechanisms regulating glucocorticoid sensitivity and resistance. Mol Cell Endocrinol (2008) 1.19
Screening for pancreatic cancer: why, how, and who? Ann Surg (2013) 1.19
Dynamic microsimulation models for health outcomes: a review. Med Decis Making (2010) 1.18
What is the point: will screening mammography save my life? BMC Med Inform Decis Mak (2009) 1.16
Trends in incidence and detection of advanced breast cancer at biennial screening mammography in The Netherlands: a population based study. Breast Cancer Res (2012) 1.16
Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years. Cancer (2012) 1.16
Secular trends in colon and rectal cancer relative survival. J Natl Cancer Inst (2013) 1.16
Heterogeneity in mammography use across the nation: separating evidence of disparities from the disproportionate effects of geography. Int J Health Geogr (2008) 1.16
Mindfulness-based stress reduction for breast cancer-a systematic review and meta-analysis. Curr Oncol (2012) 1.16
Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer. Br J Cancer (2012) 1.15
Positive predictive value of specific mammographic findings according to reader and patient variables. Radiology (2009) 1.15
The Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center: a unique resource for defining the "molecular histology" of the breast. Cancer Prev Res (Phila) (2012) 1.15
Yoga for breast cancer patients and survivors: a systematic review and meta-analysis. BMC Cancer (2012) 1.15
Application of a global proteomic approach to archival precursor lesions: deleted in malignant brain tumors 1 and tissue transglutaminase 2 are upregulated in pancreatic cancer precursors. Pancreatology (2008) 1.14
Current approaches and challenges in monitoring treatment responses in breast cancer. J Cancer (2014) 1.13
Increased expression of P-glycoprotein is associated with doxorubicin chemoresistance in the metastatic 4T1 breast cancer model. Am J Pathol (2011) 1.11
Inter-observer variability in mammography screening and effect of type and number of readers on screening outcome. Br J Cancer (2009) 1.10
Cancer statistics, 2005. CA Cancer J Clin (2005) 25.65
Cancer statistics, 2004. CA Cancer J Clin (2004) 15.72
Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science (2011) 15.45
The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med (2007) 12.23
Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst (2011) 10.29
Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst (2002) 9.45
Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst (2013) 8.75
Effect of screening mammography on breast-cancer mortality in Norway. N Engl J Med (2010) 8.71
Impact of reporting delay and reporting error on cancer incidence rates and trends. J Natl Cancer Inst (2002) 6.87
Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. Acta Trop (2003) 6.64
Patient navigation: state of the art or is it science? Cancer (2008) 5.62
Extracting a cellular hierarchy from high-dimensional cytometry data with SPADE. Nat Biotechnol (2011) 5.46
Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med (2009) 4.60
Predicting outcome after traumatic brain injury: development and international validation of prognostic scores based on admission characteristics. PLoS Med (2008) 4.60
Women older than 40 years of age and those with elevated follicle-stimulating hormone levels differ in poor response rate and embryo quality in in vitro fertilization. Fertil Steril (2003) 4.58
Estimating average annual per cent change in trend analysis. Stat Med (2009) 3.54
Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. Med Decis Making (2006) 3.50
Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts. Ann Intern Med (2014) 3.46
Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. JAMA (2010) 3.25
Cost-effectiveness analysis of a quantitative immunochemical test for colorectal cancer screening. Gastroenterology (2011) 3.08
High follicle-stimulating hormone levels should not necessarily lead to the exclusion of subfertile patients from treatment. Fertil Steril (2004) 3.08
Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999. J Natl Cancer Inst (2002) 3.04
Long-term survivors of childhood cancers in the United States. Cancer Epidemiol Biomarkers Prev (2009) 3.04
Non-small cell lung cancer: identifying prognostic imaging biomarkers by leveraging public gene expression microarray data--methods and preliminary results. Radiology (2012) 2.98
Validation and updating of predictive logistic regression models: a study on sample size and shrinkage. Stat Med (2004) 2.95
HALYS and QALYS and DALYS, Oh My: similarities and differences in summary measures of population Health. Annu Rev Public Health (2001) 2.91
Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertil Steril (2005) 2.90
Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). Int J Cancer (2007) 2.85
Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. Ann Intern Med (2012) 2.85
Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force. Ann Intern Med (2013) 2.77
Covariate adjustment in randomized controlled trials with dichotomous outcomes increases statistical power and reduces sample size requirements. J Clin Epidemiol (2004) 2.77
Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol (2009) 2.74
Trends in colorectal cancer test use among vulnerable populations in the United States. Cancer Epidemiol Biomarkers Prev (2011) 2.62
The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer (2012) 2.61
Improved estimates of cancer-specific survival rates from population-based data. J Natl Cancer Inst (2010) 2.59
Male circumcision for HIV prevention in sub-Saharan Africa: who, what and when? AIDS (2008) 2.54
Estimating average annual percent change for disease rates without assuming constant change. Biometrics (2006) 2.51
Patient age and outcome following severe traumatic brain injury: an analysis of 5600 patients. J Neurosurg (2003) 2.51
Ly6d marks the earliest stage of B-cell specification and identifies the branchpoint between B-cell and T-cell development. Genes Dev (2009) 2.46
Substantial effective sample sizes were required for external validation studies of predictive logistic regression models. J Clin Epidemiol (2005) 2.42
American College of Radiology Imaging Network digital mammographic imaging screening trial: objectives and methodology. Radiology (2005) 2.42
Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. J Natl Cancer Inst (2009) 2.35
Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey. Cancer (2007) 2.31
Should colorectal cancer screening be considered in elderly persons without previous screening? A cost-effectiveness analysis. Ann Intern Med (2014) 2.31
Impact of reduced tobacco smoking on lung cancer mortality in the United States during 1975-2000. J Natl Cancer Inst (2012) 2.30
Validity of prognostic models: when is a model clinically useful? Semin Urol Oncol (2002) 2.29
The impact of pre-exposure prophylaxis (PrEP) on HIV epidemics in Africa and India: a simulation study. PLoS One (2008) 2.23
Productivity costs of cancer mortality in the United States: 2000-2020. J Natl Cancer Inst (2008) 2.23
Multiple cancer prevalence: a growing challenge in long-term survivorship. Cancer Epidemiol Biomarkers Prev (2007) 2.21
Retrospective cost-effectiveness analysis of screening mammography. J Natl Cancer Inst (2006) 2.19
Models in the development of clinical practice guidelines. Ann Intern Med (2014) 2.18
Comparability of segmented line regression models. Biometrics (2004) 2.12
Regional differences in patient characteristics, case management, and outcomes in traumatic brain injury: experience from the tirilazad trials. J Neurosurg (2002) 2.12
Geographic disparities in cervical cancer mortality: what are the roles of risk factor prevalence, screening, and use of recommended treatment? J Rural Health (2005) 2.08
Breast cancer incidence rates in U.S. women are no longer declining. Cancer Epidemiol Biomarkers Prev (2011) 2.06
Age-conditional probabilities of developing cancer. Stat Med (2003) 2.03
Trends in esophageal adenocarcinoma incidence and mortality. Cancer (2012) 2.03
Mode of administration is important in US national estimates of health-related quality of life. Med Care (2007) 2.00
Tipping the balance of benefits and harms to favor screening mammography starting at age 40 years: a comparative modeling study of risk. Ann Intern Med (2012) 1.99
Changing area socioeconomic patterns in U.S. cancer mortality, 1950-1998: Part I--All cancers among men. J Natl Cancer Inst (2002) 1.97
Individualizing colonoscopy screening by sex and race. Gastrointest Endosc (2009) 1.96
Predicting outcome after traumatic brain injury: development and validation of a prognostic score based on admission characteristics. J Neurotrauma (2005) 1.96
Cost-effectiveness of digital mammography breast cancer screening. Ann Intern Med (2008) 1.95
Five-year follow-up of health-related quality of life after primary treatment of localized prostate cancer. Int J Cancer (2005) 1.93
Race-specific impact of natural history, mammography screening, and adjuvant treatment on breast cancer mortality rates in the United States. Cancer Epidemiol Biomarkers Prev (2010) 1.93
Empirical observations underestimate the proportion of human immunodeficiency virus infections attributable to sexually transmitted diseases in the Mwanza and Rakai sexually transmitted disease treatment trials: Simulation results. Sex Transm Dis (2006) 1.91
Clients of female sex workers in Nyanza province, Kenya: a core group in STD/HIV transmission. Sex Transm Dis (2002) 1.91
Boolean implication networks derived from large scale, whole genome microarray datasets. Genome Biol (2008) 1.91
Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. J Natl Cancer Inst (2009) 1.89
At what costs will screening with CT colonography be competitive? A cost-effectiveness approach. Int J Cancer (2009) 1.88
What proportion of episodes of gonorrhoea and chlamydia becomes symptomatic? Int J STD AIDS (2002) 1.87
Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood (2013) 1.86
Estimates and projections of value of life lost from cancer deaths in the United States. J Natl Cancer Inst (2008) 1.83
National Polyp Study data: evidence for regression of adenomas. Int J Cancer (2004) 1.83
Predicting retroperitoneal histology in postchemotherapy testicular germ cell cancer: a model update and multicentre validation with more than 1000 patients. Eur Urol (2006) 1.78
Predictors of poor ovarian response in in vitro fertilization: a prospective study comparing basal markers of ovarian reserve. Fertil Steril (2002) 1.78
A systematic comparison of microsimulation models of colorectal cancer: the role of assumptions about adenoma progression. Med Decis Making (2011) 1.77
Bias associated with self-report of prior screening mammography. Cancer Epidemiol Biomarkers Prev (2009) 1.75
A pluripotency signature predicts histologic transformation and influences survival in follicular lymphoma patients. Blood (2009) 1.74
Chapter 2: Birth-cohort-specific estimates of smoking behaviors for the U.S. population. Risk Anal (2012) 1.74
Effects of mode and order of administration on generic health-related quality of life scores. Value Health (2009) 1.72
Mobility and HIV in Tanzanian couples: both mobile persons and their partners show increased risk. AIDS (2006) 1.72
Clarifying differences in natural history between models of screening: the case of colorectal cancer. Med Decis Making (2011) 1.71
SELECTING THE NUMBER OF CHANGE-POINTS IN SEGMENTED LINE REGRESSION. Stat Sin (2009) 1.69
A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999-2010. Obstet Gynecol (2012) 1.67
The quality of medical care at the end-of-life in the USA: existing barriers and examples of process and outcome measures. Palliat Med (2004) 1.67
Extracting binary signals from microarray time-course data. Nucleic Acids Res (2007) 1.67
Short-term impact of cancer prevention and screening activities on quality of life. J Clin Oncol (2004) 1.66
Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women. Cancer Epidemiol Biomarkers Prev (2010) 1.66